Catalyst

Slingshot members are tracking this event:

ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib; decision expected in the second half of 2016.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARIA

100%
OTK.F

100%

Additional Information

Additional Relevant Details The NDA for ponatinib is supported by the Phase 1/2 study in Japanese patients, as well as the global pivotal PACE and Phase 1 trials of ponatinib. The Japanese study included 35 Japanese patients with CML or Ph+ALL who experienced failure of prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of 14.9 months at the time of analysis, the Phase 1/2 study results confirm that Iclusig demonstrates anti-leukemic activity in this patient population. Among chronic-phase patients, 65% achieved the primary efficacy endpoint of major cytogenetic response, and 35% had a major molecular response. Thirteen patients remained on therapy including 12 in chronic phase. The median duration of response had not been reached. The most common treatment-emergent adverse events in the trial of any grade were decreased platelet and neutrophil counts, pyrexia, hypertension, dry skin, rash and increased lipase. Treatment-emergent arterial thrombotic events were reported in four patients, or 11%. According to a 2011 survey by the Ministry of Health Labor and Welfare in Japan, CML occurs in approximately 1 out of 100,000 people among all age groups and it is estimated that there are approximately 11,000 patients living with CML in Japan.
http://investor.aria...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda, Pmda, Ponatinib, Iclusig, Cml, Pace, Ph+all